NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe
– Combines NewAmsterdam’s lead clinical program obicetrapib with Menarini’s deep cardiovascular disease and regional expertise – Total deal value of
Read More